ABSTRACT
BACKGROUND: Current treatments for chronic hepatitis B management include orally administered nucleos(t)ide analogues, such as tenofovir (TDF), which is an acyclic adenine nucleotide analogue used both in HBV and human immune deficiency virus (HIV). The course of HBV infection is mainly dependent on viral factors, such as HBV genotypes, immunological features and host genetic variables, but a few data are available in the context of HBV, in particular for polymorphisms of genes encoding proteins involved in drug metabolism and elimination. Consequently, the aim of this study was to evaluate the potential impact of genetic variants on TDF plasma and urine concentrations in patients with HBV, considering the role of HBV genotypes. METHODS: A retrospective cohort study at the Infectious Disease Unit of Amedeo di Savoia Hospital, Torino, Italy, was performed. Pharmacokinetic analyses were performed through liquidi chromatography, whereas pharmacogenetic analyses through real-time PCR. FINDINGS: Sixty - eight patients were analyzed: ABCC4 4976â¯C>T genetic variant showed an impact on urine TDF drug concentrations (p = 0.014). In addition, SLC22A6 453 AA was retained in the final regression multivariate model considering factors predicting plasma concentrations, while ABCC4 4976 TC/CC was the only predictor of urine concentrations in the univariate model. INTERPRETATION: In conclusion, this is the first study showing a potential impact of genetic variants on TDF plasma and urine concentrations in the HBV context, but further studies in different and larger cohorts of patients are required.
Subject(s)
Hepatitis B virus , Multidrug Resistance-Associated Proteins , Pharmacogenetics , Tenofovir , Humans , Tenofovir/therapeutic use , Tenofovir/pharmacokinetics , Male , Female , Retrospective Studies , Multidrug Resistance-Associated Proteins/genetics , Middle Aged , Pharmacogenetics/methods , Hepatitis B virus/genetics , Hepatitis B virus/drug effects , Adult , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/virology , Hepatitis B, Chronic/genetics , Antiviral Agents/pharmacokinetics , Antiviral Agents/therapeutic use , Antiviral Agents/urine , Genotype , Cohort Studies , Membrane Transport Proteins/genetics , Membrane Transport Proteins/metabolism , Polymorphism, Single Nucleotide/geneticsABSTRACT
OBJECTIVES: An unexpected drug-drug interaction has been recently reported between dolutegravir, an HIV integrase inhibitor, and valproic acid. Despite there being several potential underlying mechanisms, plasma protein displacement has been suggested. The aim of this study was to assess plasma concentrations of several antiretrovirals when administered with or without valproic acid. METHODS: We performed a therapeutic drug monitoring registry analysis and identified patients concomitantly taking antiretrovirals and valproic acid and without clinical affecting conditions or interacting drugs. RESULTS: One hundred and thirty-four patients were identified. Median (IQR) age and BMI were 49.7 years (45-56) and 23.4 kg/m2 (20.8-26.3) and 78 were male (58.2%). Despite small groups, we observed no major effect on antiretroviral exposure, even when considering highly protein-bound compounds (such as etravirine), with the exception of dolutegravir trough concentrations [median (IQR) = 132 ng/mL (62-227) in individuals on valproic acid versus 760 ng/mL (333-1407) in those not receiving valproic acid]. CONCLUSIONS: Valproic acid does not have a major effect on antiretrovirals other than dolutegravir. The mechanism of this unexpected drug-drug interaction may be the combination of protein displacement, reduced absorption and CYP3A4 induction.
Subject(s)
HIV Infections , HIV Integrase Inhibitors , Drug Interactions , HIV Infections/drug therapy , HIV Integrase Inhibitors/therapeutic use , Heterocyclic Compounds, 3-Ring/therapeutic use , Humans , Male , Oxazines , Pyridones , Valproic Acid/therapeutic useABSTRACT
BACKGROUND: Neuropsychiatric symptoms (NPs) have been reported with dolutegravir use. We hypothesized that increasing dolutegravir trough concentrations (Ctrough) and/or polymorphism in the SLC22A2 gene, encoding the organic cation transporter-2 (OCT2), which is involved in monoamine clearance in the CNS and is inhibited by dolutegravir, might be associated with NPs. METHODS: A cross-sectional cohort of HIV-positive patients treated with a dolutegravir-containing regimen underwent determination of allelic discrimination for SLC22A2 808 C â A polymorphism and dolutegravir Ctrough. The Symptom Checklist-90-R [investigating 10 psychiatric dimensions and reporting a general severity index (GSI)], a self-reported questionnaire and the Mini-International Neuropsychiatric Interview were offered to investigate current NPs. The effects of dolutegravir Ctrough and the SLC22A2 gene variant on NPs were explored by multivariable logistic regression. RESULTS: A cohort of 203 patients was analysed: 71.4% were male, with median age 51 years and 11 years of ART exposure. Median time on dolutegravir was 18 months. Dolutegravir was associated with different antiretroviral combinations (mainly lamivudine, 38.9%, and abacavir/lamivudine, 35.5%). SLC22A2 CA genotype was independently associated with an abnormal GSI [adjusted OR (aOR) 2.43; P = 0.072], anxiety (aOR 2.61; P = 0.044), hostility (aOR 3.76; P = 0.012) and with moderate to severe headache (aOR 5.55; P = 0.037), and dolutegravir Ctrough was associated with hostility (fourth versus first quartile aOR 6.70; P = 0.007) and psychoticism (fourth versus first quartile aOR 19.01; P = 0.008). Other NPs were not associated with SLC22A2 polymorphism or dolutegravir Ctrough. CONCLUSIONS: A variant of the OCT2-encoding gene, in addition to or in synergy with higher dolutegravir Ctrough, is associated with a set of NPs observed during dolutegravir therapy.
Subject(s)
Genetic Variation , HIV Infections/epidemiology , HIV Infections/genetics , Heterocyclic Compounds, 3-Ring/pharmacokinetics , Organic Cation Transporter 2/genetics , Pharmacogenomic Variants , Adult , Alleles , Antiretroviral Therapy, Highly Active , CD4 Lymphocyte Count , Cross-Sectional Studies , Female , Genotype , HIV Infections/complications , HIV Infections/drug therapy , Heterocyclic Compounds, 3-Ring/adverse effects , Humans , Male , Mental Disorders/diagnosis , Mental Disorders/etiology , Mental Disorders/psychology , Middle Aged , Oxazines , Piperazines , Public Health Surveillance , Pyridones , Severity of Illness Index , Symptom Assessment , Viral LoadABSTRACT
Tenofovir disoproxil fumarate (TDF) is a very effective antiviral drug that has been associated with tubular dysfunction. The aim of this study was to analyze the demographic, pharmacokinetic, and pharmacogenetic variables associated with TDF discontinuation for renal outcomes in stable HIV-positive patients using multivariable analyses. Three hundred and four patients were included (73% male, with median age and eCrCl of 45.3 years and 90.9 mL/min, respectively). After a median follow-up of 28.3 months, 27 patients discontinued TDF for renal adverse events [persistent urinary abnormalities (n = 21) or eCrCl < 60 mL/min (n = 6)] providing an incidence of 3.77 events per 100 patient-year. The probability of TDF discontinuation was higher with several features (male gender, older age, not Caucasians ancestry, absence of intravenous drug abuse, protease inhibitors, previous indinavir, HCV-positivity, lower CD4 cell count, detectable HIV-RNA, lower eCrCl, spot-urine proteinuria) and higher tenofovir concentrations but not genetic variants. Tenofovir plasma concentrations were prognostic of TDF discontinuation for renal adverse events suggesting that dose-adjustment may be warranted for long-term safety.
Subject(s)
Anti-HIV Agents/therapeutic use , HIV Infections/drug therapy , Kidney/drug effects , Protease Inhibitors/therapeutic use , Tenofovir/therapeutic use , Adult , CD4-Positive T-Lymphocytes/drug effects , Cross-Sectional Studies , Female , Humans , Male , Middle Aged , Precision Medicine/methodsABSTRACT
ß-Thalassemia patients develop deficiency in vitamin D absorption and liver hydroxylation, resulting in extremely low calcitriol levels. We explored the role of single-nucleotide polymorphisms (SNPs) involved in vitamin D metabolism, transport and activity on deferasirox pharmacokinetics and outcomes (effectiveness trough levels (Ctrough) and the area under the curve (AUC) cutoffs of 20 µg ml-1 and 360 µg ml-1 h-1, respectively; nonresponse AUC limit of 250 µg ml-1 h-1). Ninety-nine ß-thalassemic patients were enrolled. Drug plasma Ctrough and AUC were measured by the high-performance liquid chromatography system coupled with an ultraviolet determination method. Allelic discrimination for VDR, CYP24A1, CYP27B1 and GC gene SNPs was performed by real-time PCR. CYP24A1 22776 TT significantly influenced Cmin and negatively predicted it in regression analysis. CYP24A1 3999 CC was associated with Ctrough and Cmin and was a negative predictor of Tmax, whereas CYP24A1 8620 GG seemed to have a role in Ctrough, AUC, t1/2 and Cmin, and was an AUC negative predictor factor. Considering treatment outcome, Cdx2 and GC 1296 were retained in regression analysis as AUC efficacy cutoff negative predictors.
Subject(s)
Deferasirox/administration & dosage , Receptors, Calcitriol/genetics , Vitamin D-Binding Protein/genetics , Vitamin D3 24-Hydroxylase/genetics , beta-Thalassemia/drug therapy , Adolescent , Adult , Alleles , Deferasirox/adverse effects , Deferasirox/blood , Female , Genotype , Humans , Liver/drug effects , Liver/metabolism , Male , Middle Aged , Polymorphism, Single Nucleotide , Treatment Outcome , Vitamin D/genetics , Vitamin D/metabolism , Vitamin D Deficiency/drug therapy , Vitamin D Deficiency/genetics , Vitamin D Deficiency/pathology , Young Adult , beta-Thalassemia/genetics , beta-Thalassemia/pathologyABSTRACT
In this prospective study, we evaluated the effectiveness and tolerability of novel therapies against hepatitis C virus (HCV) in a cohort of PWID enrolled at our centre from April 2015 to July 2016. In this analysis, a total of 174 patients were included: eleven (6.3%) were treated with pegylated interferon (PEG-IFN) and ribavirin (RBV) containing regimens, 163 (93.7%) with IFN-free treatments. RBV has been used in 70 patients (40.2%); 59 (33.9%) patients were in opioid substitution therapy (OST) with methadone or buprenorphine. Overall, sustained virological response (SVR) has been observed in 162 subject (93.1%), breakthrough (BT) in three (1.7%), relapse in one (0.6%) and dropout in eight (4.6%). Treatment was interrupted for clinical conditions in seven patients: six (3.4%) had hepatic decompensation and one died for hepatocellular carcinoma (HCC). In multivariate analysis, predictive factors of treatment failure were as follows: albumin level below 3 g/dL (OR=7.190; 95% IC=1.236-41.837; P<.001), MELD score >10 (OR=5.886; 95% IC=1.411-35.994; P<.001) and years of HCV infection >20 (OR=1.286; 95% IC=0.556-9.455; P=.016). In conclusion, treatment with DAAs was effective and well tolerated in PWID; cirrhotic subjects with MELD > 10 and albumin low level showed a higher risk of developing serious adverse events and treatment failure.
Subject(s)
Antiviral Agents/therapeutic use , Drug Users , Hepacivirus/drug effects , Hepatitis C/drug therapy , Hepatitis C/virology , Adult , Aged , Antiviral Agents/pharmacology , Comorbidity , Drug Therapy, Combination , Elasticity Imaging Techniques , Female , Genotype , Hepacivirus/genetics , Hepatitis C/complications , Hepatitis C/transmission , Humans , Liver Cirrhosis/diagnostic imaging , Liver Cirrhosis/etiology , Liver Cirrhosis/pathology , Male , Middle Aged , Odds Ratio , Prognosis , Prospective Studies , ROC Curve , Risk Factors , Treatment Outcome , Viral LoadSubject(s)
Benzoates/pharmacokinetics , Benzoates/therapeutic use , Iron Chelating Agents/pharmacokinetics , Iron Chelating Agents/therapeutic use , Triazoles/pharmacokinetics , Triazoles/therapeutic use , beta-Thalassemia/drug therapy , Area Under Curve , Benzoates/blood , Deferasirox , Female , Genotype , Humans , Male , Pharmacogenetics , Polymorphism, Single Nucleotide , Treatment Outcome , Triazoles/blood , beta-Thalassemia/blood , beta-Thalassemia/genetics , beta-Thalassemia/metabolismABSTRACT
The HIV virus and hepatitis B virus nucleotide reverse transcriptase inhibitor tenofovir has been associated with proximal tubular toxicity; the latter was found to be predicted by plasma concentrations and with single-nucleotide polymorphisms in transporters-encoding genes. A cross-sectional analysis in adult HIV-positive patients with estimated creatinine clearance >60 ml min-1 was performed. Twelve-hour plasma and urinary tenofovir concentrations and single-nucleotide polymorphisms in several transporter-encoding genes were analysed. In 289 patients 12-h tenofovir plasma, urinary and urinary to plasma ratios were 69 ng ml-1 (interquartile range 51.5-95), 24.3 mg ml-1 (14.3-37.7) and 384 (209-560). At multivariate analysis estimated creatinine clearance, protease inhibitors co-administration and SLC28A2 CT/TT genotypes were independently associated with plasma tenofovir exposure; ABCC10 GA/AA genotypes and protease inhibitor co-administration were independently associated with the urinary to plasma tenofovir ratio. Tenofovir clearance was associated with genetic polymorphisms in host genes and with co-administered drugs: if confirmed by ongoing studies these data may inform treatment tailoring and/or dose reductions.
Subject(s)
Anti-HIV Agents/pharmacokinetics , Membrane Transport Proteins/genetics , Multidrug Resistance-Associated Proteins/genetics , Pharmacogenetics/methods , Pharmacogenomic Variants , Polymorphism, Single Nucleotide , Reverse Transcriptase Inhibitors/pharmacokinetics , Tenofovir/pharmacokinetics , Adult , Anti-HIV Agents/blood , Anti-HIV Agents/urine , Creatinine/blood , Creatinine/urine , Cross-Sectional Studies , Drug Interactions , Drug Therapy, Combination , Female , Heterozygote , Homozygote , Humans , Kidney/drug effects , Kidney/metabolism , Kidney/physiopathology , Linear Models , Male , Membrane Transport Proteins/metabolism , Middle Aged , Multidrug Resistance-Associated Proteins/metabolism , Multivariate Analysis , Phenotype , Protease Inhibitors/pharmacokinetics , Renal Elimination , Reverse Transcriptase Inhibitors/adverse effects , Reverse Transcriptase Inhibitors/blood , Reverse Transcriptase Inhibitors/urine , Risk Assessment , Risk Factors , Tenofovir/adverse effects , Tenofovir/blood , Tenofovir/urineABSTRACT
BACKGROUND: Atazanavir without ritonavir, despite efficacy and tolerability, shows low plasma concentrations that warrant optimization. METHODS: In a randomized, controlled, pilot trial, stable HIV-positive patients on atazanavir/ritonavir (with tenofovir/emtricitabine) were switched to atazanavir. In the standard-dose arm, atazanavir was administered as 400 mg once daily, while according to patients' genetics (PXR, ABCB1 and SLCO1B1), in the pharmacogenetic arm: patients with unfavourable genotypes received 200 mg of atazanavir twice daily. EudraCT number: 2009-014216-35. RESULTS: Eighty patients were enrolled with balanced baseline characteristics. The average atazanavir exposure was 253 ng/mL (150-542) in the pharmacogenetic arm versus 111 ng/mL (64-190) in the standard-dose arm (Pâ<â0.001); 28 patients in the pharmacogenetic arm (75.7%) had atazanavir exposure >150 ng/mL versus 14 patients (38.9%) in the standard-dose arm (Pâ=â0.001). Immunovirological and laboratory parameters had a favourable outcome throughout the study with non-significant differences between study arms. CONCLUSIONS: Atazanavir plasma exposure is higher when the schedule is chosen according to the patient's genetic profile.
Subject(s)
Anti-Retroviral Agents/administration & dosage , Anti-Retroviral Agents/pharmacokinetics , Atazanavir Sulfate/administration & dosage , Atazanavir Sulfate/pharmacokinetics , HIV Infections/drug therapy , Pharmacogenetics/methods , Plasma/chemistry , ATP Binding Cassette Transporter, Subfamily B/genetics , Adult , Female , Genetic Markers , Genotype , Humans , Liver-Specific Organic Anion Transporter 1 , Male , Middle Aged , Organic Anion Transporters/genetics , Peroxisome-Targeting Signal 1 Receptor , Pilot Projects , Receptors, Cytoplasmic and Nuclear/geneticsABSTRACT
In HBV-infected patients, the vitamin D deficiency has been related to chronic liver diseases, progression of hepatic fibrosis and poor response to the treatment. The CYP27B1 gene, which encodes the 1-α-hidroxylase and involved in the 1,25-dihydroxyvitamin D synthesis, was recently associated to type-1 diabetes, autoimmune disorders and treatment response in HCV. Then, we aimed to investigate the role of CYP27B1 polymorphisms in HBV treatment with PEG-IFN. We retrospectively enrolled 190 patients with chronic hepatitis B HBeAg negative treated for 48 weeks with PEG-IFN α-2a. We examined the role of rs4646536 CYP27B1 SNP (CYP27B1+2838) according to virological and serological response. Our results showed that the TT genotype of CYP27B1+2838 was significantly prevalent in patients with end-of-therapy virological response (37.6%) vs CT/CC (9.4%) (P < 0.001). Virological relapse was prevalent in patients with CT/CC genotype (12.6%) vs TT genotype (2.1%) (P < 0.001). TT genotype was also related to HBsAg loss (P = 0.004) and anti-HBs appearance (P = 0.002). In the multivariate analysis, the TT genotype resulted to be a good positive predictor of sustained virological response (OR = 5.632, IC = 1.938-16.368, P = 0.001) and serological response (OR = 6.161, IC = 1.856-20.457, P = 0.003). The CYP27B1+2838 polymorphism may be useful as pretreatment factor to selection of patients with higher probability of response to therapy.
Subject(s)
25-Hydroxyvitamin D3 1-alpha-Hydroxylase/genetics , Antiviral Agents/therapeutic use , Hepatitis B, Chronic/drug therapy , Hepatitis B, Chronic/genetics , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Polymorphism, Single Nucleotide , Promoter Regions, Genetic , Adult , Aged , Female , Genotype , Hepatitis B e Antigens/blood , Hepatitis B e Antigens/immunology , Hepatitis B virus/genetics , Hepatitis B virus/immunology , Hepatitis B, Chronic/immunology , Hepatitis B, Chronic/virology , Humans , Male , Middle Aged , Recombinant Proteins/therapeutic use , Retrospective Studies , Treatment Outcome , Viral Load , Young AdultABSTRACT
Deferasirox (DFX) is the only once-daily oral chelator for iron overload and its pharmacokinetic has been related with response to therapy. Our aim was to evaluate DFX plasma concentrations according to single-nucleotide polymorphisms in genes involved in its metabolism (UGT1A1, UGT1A3, CYP1A1, CYP1A2 and CYP2D6) and elimination (MRP2 and BCRP1). Further aim was to define a plasma concentration cutoff value predicting an adequate response to therapy. Plasma concentrations were determined at the end of dosing interval (C trough) using an high-performance liquid chromatography-ultraviolet method. Allelic discrimination was performed by real-time PCR. C trough levels were influenced by UGT1A1C>T rs887829, CYP1A1C>A rs2606345, CYP1A2A>C rs762551, CYP1A2C>T rs2470890 and MRP2G>A rs2273697 polymorphisms. A DFX plasma efficacy cutoff value of 20,000 ng ml(-1) was identified; CYP1A1C>A rs2606345 AA and CYP1A2C>T rs2470890 TT genotypes may predict this value, suggesting a negative predictive role in therapy efficacy. Our data suggest the feasibility of a pharmacogenetic-based DFX dose personalization.
Subject(s)
Benzoates/therapeutic use , Iron Overload/drug therapy , Iron Overload/genetics , Polymorphism, Single Nucleotide/genetics , Triazoles/therapeutic use , ATP Binding Cassette Transporter, Subfamily G, Member 2 , ATP-Binding Cassette Transporters/genetics , Adult , Alleles , Chromatography, High Pressure Liquid/methods , Cohort Studies , Cytochrome P-450 Enzyme System/genetics , Deferasirox , Female , Genotype , Glucuronosyltransferase/genetics , Humans , Male , Multidrug Resistance-Associated Protein 2 , Multidrug Resistance-Associated Proteins/genetics , Neoplasm Proteins/geneticsABSTRACT
The new standard of care for treatment for infection with genotype 1a/b of HCV now is the combination of telaprevir (TLV) with ribavirin (RBV) and pegylated interferon (Peg-IFN). Although this new therapy gives a higher response rate than the Peg-IFNα plus RBV treatment, a greatly higher rate of anaemia onset has been reported in all clinical trials. Because haemolysis is a typical concentration-dependent side effect of RBV, modulated by ITPA gene polymorphisms, we aimed to compare the early RBV plasma exposure of nine patients after 2 weeks of treatment with triple therapy with RBV concentrations of 187 patients treated with RBV and Peg-IFNα over the same time scale; this comparison was performed also stratifying patients according to ITPA polymorphism genotype and anaemia onset after 1 month of treatment. All TLV-treated patients had unfavourable ITPA genetic profile and developed anaemia. Moreover, both the rate of anaemia onset and the haemoglobin loss at 1 month were significantly higher in patients treated with TLV. This observation has been confirmed also in patients with the same ITPA genetic profile in double therapy. Strikingly, also early RBV plasma concentrations were significantly higher in patients treated with TLV. These unbiased results confirm the observations recently reported and suggest that the high rate of anaemia onset could be mainly due to the increased RBV exposure, probably caused by a 'boosting effect' by TLV. These data highlight the great importance of early therapeutic drug monitoring of RBV in the management of anaemia in the triple therapy.